JNK2alpha2/SAPK1a, active

N-terminal 6His-tagged recombinant, human full length JNK2α2/SAPK1a.

Catalog #: 14-329

$399.00$2,989.00


Inquire
Biological Information
Background Information:
c-Jun N-terminal kinases (JNKs), a stress-activated protein kinase (SAPK), is involved in cellular responses to environmental stresses. JNK kinases can be activated by stimuli such as UV light, radiation, protein synthesis inhibitors, ceramide, DNA-damaging drugs, chemopreventive drugs, TNF-a, and interleukin 1. JNK binds to an NH2-terminal region of ATF2 and c-Jun and phosphorylates two sites within the activation domain of each transcription factor. Three JNK genes (Jnk1, -2 and -3) have been identified in humans; however, splice variants result in a total of 10 isoforms. Therapeutic inhibition of JNK may provide clinical benefit in diseases as diverse as immune inflammatory (joint, bowel, pulmonary), ischemic injury (brain, cardiac) and neurodegenerative (Alzheimer's, Parkinson's) diseases. EMBL L31951. Recombinant protein contains the amino acid residue substitution S51N with respect to EMBL L31951. This conflict is reported in GenBank U09759 and the following GenBank ESTs, AL532378, AL550761, BI333490.
Target Class:
Kinase
Family:
Ser/Thr Kinase; MAPK; JNK subfamily
Accession Number:
NM_002752.3; NM_139068.1; NM_139069.1; NM_139070.1
Target Name:
JNK2α2/SAPK1a
Target Aliases:
MAPK9, JNK2B, JNK-55, JNK2, JNK2BETA, p54aSAPK, JNK2ALPHA, PRKM9, JNK2A
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
6 months at -70°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Datasheets

14-329x Datasheet

View Document